{"id":37208,"date":"2026-07-04T07:50:33","date_gmt":"2026-07-04T02:20:33","guid":{"rendered":"https:\/\/atsixty.com\/?p=37208"},"modified":"2026-07-04T07:50:34","modified_gmt":"2026-07-04T02:20:34","slug":"psychopharmacology-ii-antipsychotics-movement-disorders-clozapine","status":"publish","type":"post","link":"https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/","title":{"rendered":"Psychopharmacology II \u2014 Antipsychotics, Movement Disorders & Clozapine"},"content":{"rendered":"\n\n\n\n\nMorning Rounds · Psychiatry · Psychopharmacology II<\/title>\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&family=Source+Serif+4:ital,wght@0,300;0,400;0,600;1,400&display=swap\" rel=\"stylesheet\">\n<style>\n#psy05 *,#psy05 *::before,#psy05 *::after{box-sizing:border-box;margin:0;padding:0}\n#psy05{\n --py:#34547A;\n --py-light:#4A6B95;\n --py-pale:#E8EEF5;\n --py-dark:#243C56;\n --correct:#2D6B47;--correct-bg:#EAF6EF;--correct-border:#3A9960;\n --wrong:#B83232;--wrong-bg:#FDF0F0;--wrong-border:#E53935;\n --ink:#1F2B38;--ink-mid:#3D4F61;--ink-soft:#7E8FA0;\n --line:#D8E0E8;--cream:#F7F9FB;--warm:#FDFEFE;\n font-family:'Source Serif 4',Georgia,serif;\n font-size:16px;color:var(--ink);background:var(--cream);\n line-height:1.7;padding:0 0 64px;\n}\n#psy05 .mr-header{background:var(--py);color:#EEF3FA;padding:34px 24px 28px;text-align:center}\n#psy05 .mr-eyebrow{font-size:0.68rem;letter-spacing:0.18em;text-transform:uppercase;font-weight:600;opacity:0.65;margin-bottom:10px}\n#psy05 .mr-title{font-family:'Playfair Display',serif;font-size:1.75rem;font-weight:700;line-height:1.2;margin-bottom:4px}\n#psy05 .mr-title em{font-style:italic;font-weight:400;opacity:0.88}\n#psy05 .mr-subtitle{font-size:0.82rem;opacity:0.7;margin-top:8px;font-style:italic}\n#psy05 .mr-chips{display:flex;justify-content:center;gap:10px;margin-top:18px;flex-wrap:wrap}\n#psy05 .mr-chip{background:rgba(255,255,255,0.13);border:1px solid rgba(255,255,255,0.22);border-radius:20px;padding:4px 13px;font-size:0.73rem}\n#psy05 .mr-sentinel{height:1px}\n#psy05 .mr-progress{position:fixed;top:0;left:0;right:0;z-index:9999;background:var(--warm);border-bottom:1px solid var(--line);box-shadow:0 2px 12px rgba(31,43,56,0.08);padding:9px 16px;display:none}\n#psy05 .mr-progress.visible{display:block}\n#psy05 .mr-prog-inner{max-width:720px;margin:0 auto;display:flex;align-items:center;justify-content:center}\n#psy05 .mr-pips{display:flex;align-items:center;justify-content:center}\n#psy05 .mr-pip-wrap{display:flex;align-items:center}\n#psy05 .mr-pip-line{width:28px;height:2px;background:var(--line);transition:background 0.35s}\n#psy05 .mr-pip-line.done{background:var(--py)}\n#psy05 .mr-pip{width:28px;height:28px;border-radius:50%;border:2px solid var(--line);background:var(--warm);display:flex;align-items:center;justify-content:center;font-size:0.63rem;font-weight:700;color:var(--ink-soft);transition:all 0.3s;flex-shrink:0}\n#psy05 .mr-pip.correct{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#psy05 .mr-pip.wrong{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#psy05 .mr-body{max-width:720px;margin:0 auto;padding:0 16px}\n#psy05 .mr-case{background:var(--warm);border:1px solid var(--line);border-left:4px solid var(--py);border-radius:10px;margin:28px 0;overflow:hidden;box-shadow:0 1px 6px rgba(31,43,56,0.05)}\n#psy05 .mr-case-top{padding:16px 20px 14px;display:flex;gap:14px;align-items:flex-start}\n#psy05 .mr-num{font-family:'Playfair Display',serif;font-size:2.2rem;font-weight:700;color:var(--py);opacity:0.16;line-height:1;margin-top:-2px;flex-shrink:0}\n#psy05 .mr-meta{flex:1}\n#psy05 .mr-tag{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--py);opacity:0.8;margin-bottom:5px}\n#psy05 .mr-stem{font-size:0.94rem;color:var(--ink);line-height:1.72}\n#psy05 .mr-stem strong{font-weight:600}\n#psy05 .mr-stem em{font-style:italic}\n#psy05 .mr-rule{height:1px;background:var(--line);margin:0 20px}\n#psy05 .mr-opts{padding:12px 20px 16px;display:flex;flex-direction:column;gap:8px}\n#psy05 .mr-opt{display:flex;align-items:flex-start;gap:11px;padding:10px 14px;border:1.5px solid var(--line);border-radius:8px;cursor:pointer;background:var(--warm);transition:border-color 0.15s,background 0.15s;-webkit-tap-highlight-color:transparent}\n#psy05 .mr-opt:hover{border-color:var(--py);background:var(--py-pale)}\n#psy05 .mr-opt.locked{cursor:default}\n#psy05 .mr-opt.locked:hover{border-color:var(--line);background:var(--warm)}\n#psy05 .mr-opt.correct{border-color:var(--correct-border);background:var(--correct-bg);cursor:default}\n#psy05 .mr-opt.correct:hover{border-color:var(--correct-border);background:var(--correct-bg)}\n#psy05 .mr-opt.wrong{border-color:var(--wrong-border);background:var(--wrong-bg);cursor:default}\n#psy05 .mr-opt.wrong:hover{border-color:var(--wrong-border);background:var(--wrong-bg)}\n#psy05 .mr-opt.dimmed{opacity:0.35;cursor:default}\n#psy05 .mr-opt.dimmed:hover{border-color:var(--line);background:var(--warm)}\n#psy05 .mr-ltr{flex-shrink:0;width:20px;height:20px;border-radius:50%;border:1.5px solid var(--line);display:flex;align-items:center;justify-content:center;font-size:0.62rem;font-weight:700;color:var(--ink-soft);margin-top:2px;transition:all 0.15s}\n#psy05 .mr-opt.correct .mr-ltr{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#psy05 .mr-opt.wrong .mr-ltr{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#psy05 .mr-opt-text{font-size:0.9rem;color:var(--ink-mid);line-height:1.58}\n#psy05 .mr-opt.correct .mr-opt-text{color:var(--correct);font-weight:600}\n#psy05 .mr-opt.wrong .mr-opt-text{color:var(--wrong)}\n#psy05 .mr-exp{display:none;border-top:1px solid #C9D6E3;background:linear-gradient(180deg,#E4ECF4 0%,#EFF4F9 100%);padding:13px 20px 15px}\n#psy05 .mr-exp-lbl{font-size:0.61rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;color:#1F3A52;margin-bottom:6px}\n#psy05 .mr-exp-text{font-size:0.86rem;color:#1A2B38;line-height:1.68}\n#psy05 .mr-exp-text strong{font-weight:600}\n#psy05 .mr-exp-text em{font-style:italic}\n#psy05 .mr-img-wrap{margin-top:14px;background:var(--warm);border:1px solid var(--line);border-radius:8px;padding:14px;text-align:center}\n#psy05 .mr-img-wrap figcaption{font-size:0.73rem;color:var(--ink-soft);font-style:italic;margin-top:8px;line-height:1.4}\n#psy05 .mr-submit-wrap{text-align:center;padding:28px 16px 8px}\n#psy05 .mr-btn{background:var(--py);color:#EEF3FA;border:none;border-radius:8px;padding:13px 44px;font-family:'Playfair Display',serif;font-size:1rem;font-weight:700;cursor:pointer;box-shadow:0 2px 8px rgba(52,84,122,0.28)}\n#psy05 .mr-btn:hover{background:var(--py-dark)}\n#psy05 .mr-score{display:none;background:var(--warm);border:1px solid var(--line);border-top:4px solid var(--py);border-radius:10px;margin:24px 0 0;box-shadow:0 2px 12px rgba(31,43,56,0.08);overflow:hidden}\n#psy05 .mr-score-in{padding:28px 24px;text-align:center}\n#psy05 .mr-score-ey{font-size:0.66rem;letter-spacing:0.14em;text-transform:uppercase;color:var(--ink-soft);margin-bottom:12px;font-weight:600}\n#psy05 .mr-ring{width:98px;height:98px;border-radius:50%;background:conic-gradient(var(--py) 0%,var(--line) 0%);display:flex;align-items:center;justify-content:center;margin:0 auto 16px;position:relative}\n#psy05 .mr-ring::before{content:'';position:absolute;width:76px;height:76px;border-radius:50%;background:var(--warm)}\n#psy05 .mr-ring-in{position:relative;display:flex;flex-direction:column;align-items:center;line-height:1.2}\n#psy05 .mr-ring-pct{font-family:'Playfair Display',serif;font-size:1.3rem;font-weight:700;color:var(--py)}\n#psy05 .mr-ring-sub{font-size:0.54rem;color:var(--ink-soft);text-transform:uppercase;letter-spacing:0.06em}\n#psy05 .mr-score-title{font-family:'Playfair Display',serif;font-size:1.15rem;font-weight:700;color:var(--ink);margin-bottom:4px}\n#psy05 .mr-score-net{font-size:0.9rem;color:var(--py);font-weight:600;margin-bottom:4px}\n#psy05 .mr-verdict{font-size:0.83rem;color:var(--ink-soft);font-style:italic;margin-bottom:18px;padding:0 12px}\n#psy05 .mr-bands{display:flex;justify-content:center;gap:10px;flex-wrap:wrap}\n#psy05 .mr-band{padding:5px 13px;border-radius:16px;font-size:0.78rem;font-weight:600}\n#psy05 .mr-band-c{background:var(--correct-bg);color:var(--correct)}\n#psy05 .mr-band-w{background:var(--wrong-bg);color:var(--wrong)}\n#psy05 .mr-band-s{background:var(--py-pale);color:var(--py)}\n#psy05 .mr-retry{display:block;margin:18px auto 4px;background:transparent;border:2px solid var(--py);color:var(--py);border-radius:8px;padding:9px 28px;font-family:'Playfair Display',serif;font-size:0.92rem;font-weight:700;cursor:pointer}\n#psy05 .mr-retry:hover{background:var(--py);color:#EEF3FA}\n@media(max-width:480px){#psy05 .mr-title{font-size:1.4rem}#psy05 .mr-num{font-size:1.7rem}#psy05 .mr-stem{font-size:0.9rem}#psy05 .mr-opt-text{font-size:0.86rem}}\n<\/style>\n\n<div id=\"psy05\">\n\n <div class=\"mr-header\">\n <div class=\"mr-eyebrow\">Morning Rounds · Psychiatry Series · Round 05<\/div>\n <div class=\"mr-title\">\n Psychopharmacology II —<br><em>Antipsychotics, Movement Disorders & Clozapine<\/em>\n <\/div>\n <div class=\"mr-subtitle\">Five cases · EPS mechanism, NMS vs. serotonin syndrome, tardive dyskinesia & metabolic burden · Trust your instinct<\/div>\n <div class=\"mr-chips\">\n <span class=\"mr-chip\">5 Cases<\/span>\n <span class=\"mr-chip\">+4 \/ −1 scoring<\/span>\n <span class=\"mr-chip\">Options reshuffled<\/span>\n <\/div>\n <\/div>\n\n <div class=\"mr-sentinel\" id=\"psy05-sentinel\"><\/div>\n\n <div class=\"mr-progress\" id=\"psy05-progress\">\n <div class=\"mr-prog-inner\">\n <div class=\"mr-pips\" id=\"psy05-pips\"><\/div>\n <\/div>\n <\/div>\n\n <div class=\"mr-body\">\n <div id=\"psy05-cases\"><\/div>\n <div class=\"mr-submit-wrap\">\n <button class=\"mr-btn\" id=\"psy05-submit\">Submit for Debrief<\/button>\n <\/div>\n <div class=\"mr-score\" id=\"psy05-score\">\n <div class=\"mr-score-in\">\n <div class=\"mr-score-ey\">Round Complete<\/div>\n <div class=\"mr-ring\" id=\"psy05-ring\">\n <div class=\"mr-ring-in\">\n <span class=\"mr-ring-pct\" id=\"psy05-pct\">0%<\/span>\n <span class=\"mr-ring-sub\">net<\/span>\n <\/div>\n <\/div>\n <div class=\"mr-score-title\">Your Debrief<\/div>\n <div class=\"mr-score-net\" id=\"psy05-net\"><\/div>\n <div class=\"mr-verdict\" id=\"psy05-verdict\"><\/div>\n <div class=\"mr-bands\">\n <span class=\"mr-band mr-band-c\" id=\"psy05-ct-c\"><\/span>\n <span class=\"mr-band mr-band-w\" id=\"psy05-ct-w\"><\/span>\n <span class=\"mr-band mr-band-s\" id=\"psy05-ct-s\"><\/span>\n <\/div>\n <button class=\"mr-retry\" id=\"psy05-retry\">↻ New Round<\/button>\n <\/div>\n <\/div>\n <\/div>\n\n<\/div><!-- end #psy05 -->\n\n<script>\n(function () {\n 'use strict';\n\n var NS = 'psy05';\n var TOTAL = 5;\n var MAX = 20;\n var LTRS = ['A','B','C','D'];\n\n var QS = [{\"id\": 1, \"tag\": \"Typical vs. Atypical Antipsychotics: EPS Risk\", \"stem\": \"A 32-year-old with first-episode schizophrenia is being started on an antipsychotic. What mechanistic difference between typical and atypical antipsychotics explains the lower extrapyramidal side-effect burden of the atypical agents?\", \"correct\": \"Atypicals combine D2 blockade with 5-HT2A antagonism, which disinhibits nigrostriatal dopamine and reduces EPS.\", \"opts\": [\"Atypicals combine D2 blockade with 5-HT2A antagonism, which disinhibits nigrostriatal dopamine and reduces EPS.\", \"Atypicals block D1 receptors exclusively, leaving D2 entirely unaffected and eliminating the nigrostriatal EPS mechanism.\", \"Atypicals work via serotonin selectivity alone with no dopaminergic activity, explaining their negligible EPS profile across all agents.\", \"Atypicals have lower EPS because they cross the blood-brain barrier slowly, giving the nigrostriatal pathway time to adapt.\"], \"exp\": \"Typical antipsychotics work mainly through D2 blockade; nigrostriatal D2 blockade drives EPS. Atypicals (e.g., risperidone, olanzapine, quetiapine) combine D2 antagonism with serotonin 5-HT2A antagonism — the 5-HT2A blockade in the nigrostriatal pathway disinhibits dopamine release there, partially offsetting the D2 block and reducing EPS risk. This dual mechanism is the core pharmacological rationale.<br><br>Atypicals are not purely D1-acting — D2 blockade remains central to their antipsychotic effect; they just sit at D2 with lower affinity and faster dissociation than typicals. And they retain meaningful dopaminergic activity; their advantage comes from the serotonergic co-blockade, not an absence of dopamine modulation. Blood-brain barrier kinetics do not explain the EPS difference — the mechanism is receptor-level, at the nigrostriatal pathway specifically.\", \"imgId\": null}, {\"id\": 2, \"tag\": \"Neuroleptic Malignant Syndrome vs. Serotonin Syndrome\", \"stem\": \"Patient A on haloperidol develops hyperthermia, lead-pipe rigidity, autonomic instability, and elevated CK over 48 hours. Patient B, just switched from an SSRI to an MAOI without washout, develops fever, clonus, hyperreflexia, and agitation within hours. Which syndrome is which, and what drug is used in NMS?\", \"correct\": \"Patient A: NMS — dantrolene or bromocriptine; Patient B: serotonin syndrome — cyproheptadine is a specific serotonin-antagonist adjunct.\", \"opts\": [\"Patient A: NMS — dantrolene or bromocriptine; Patient B: serotonin syndrome — cyproheptadine is a specific serotonin-antagonist adjunct.\", \"Patient A: serotonin syndrome; Patient B: NMS — both treated identically with dantrolene as the single pharmacological specific in each.\", \"Both are NMS, since any antipsychotic or antidepressant class can produce the same syndrome, with bromocriptine required in each case.\", \"Patient A: NMS; Patient B: anticholinergic toxidrome, since the SSRI-MAOI combination triggers muscarinic excess rather than serotonin excess.\"], \"exp\": \"NMS is caused by antipsychotic-mediated dopamine blockade — it develops over days with 'lead-pipe' rigidity, hyperthermia, and markedly raised CK. Dantrolene (reduces muscle rigidity via calcium release inhibition) and bromocriptine (dopamine agonist, counteracts D2 blockade) are the pharmacological treatments. Serotonin syndrome is caused by excess serotonergic activity — onset is rapid, rigidity is 'clonus\/hyperreflexia' rather than lead-pipe, and cyproheptadine (a serotonin antagonist) is a specific adjunct alongside supportive care.<br><br>The onset speed, rigidity type, and drug context are the distinguishing features — these are clearly two different syndromes. Dantrolene is not the sole agent in NMS (bromocriptine is equally relevant), and it has no role in serotonin syndrome. The SSRI-MAOI combination produces serotonin excess, not anticholinergic toxidrome — muscarinic excess presents with dry flushed skin, urinary retention, and delirium, not clonus and hyperreflexia.\", \"imgId\": null}, {\"id\": 3, \"tag\": \"Tardive Dyskinesia: Risk, Recognition & Valbenazine\", \"stem\": \"An older patient on a typical antipsychotic for three years develops repetitive, involuntary lip-smacking and tongue-protrusion movements. What is the diagnosis, what are the key risk factors, and what pharmacological option now exists beyond simply stopping the offending drug?\", \"correct\": \"Tardive dyskinesia — long-duration typical antipsychotic use is the main risk; valbenazine (VMAT2 inhibitor) is now a licensed treatment.\", \"opts\": [\"Tardive dyskinesia — long-duration typical antipsychotic use is the main risk; valbenazine (VMAT2 inhibitor) is now a licensed treatment.\", \"Acute dystonia from cumulative dopamine blockade — the priority is to increase the antipsychotic dose immediately to override this effect.\", \"Tardive dyskinesia — best managed by switching to a higher-potency typical antipsychotic, which reverses orofacial movements most reliably.\", \"Akathisia manifesting as orofacial movements, best treated with a short-acting benzodiazepine taken only at the time movements are occurring.\"], \"exp\": \"Tardive dyskinesia is a late-onset movement disorder from chronic dopamine receptor blockade — orofacial movements (lip smacking, tongue protrusion, chewing) are classic. Risk increases with duration of typical antipsychotic use, older age, female sex, and history of acute EPS. Valbenazine (and deutetrabenazine) are VMAT2 inhibitors that reduce presynaptic dopamine release and are now licensed treatments for TD beyond the traditional approach of dose reduction or switching to an atypical.<br><br>Acute dystonia appears early (hours to days after starting), not after three years, and increasing the antipsychotic dose worsens TD rather than resolving it. Switching to a higher-potency typical would increase the very risk factor driving TD. Akathisia is a subjective restlessness with motor overflow, distinct from the stereotyped orofacial movements of TD, and benzodiazepines are not a specific treatment for TD movements.\", \"imgId\": null}, {\"id\": 4, \"tag\": \"Clozapine: Indication, Agranulocytosis & Monitoring\", \"stem\": \"A patient with schizophrenia has had inadequate response to two adequate trials of different antipsychotics. Clozapine is being considered. What is its specific indication, its most dangerous adverse effect, and the monitoring protocol that mandates it?\", \"correct\": \"Clozapine is for treatment-resistant schizophrenia; agranulocytosis is the key risk, requiring weekly then fortnightly FBC monitoring.\", \"opts\": [\"Clozapine is for treatment-resistant schizophrenia; agranulocytosis is the key risk, requiring weekly then fortnightly FBC monitoring.\", \"Clozapine is the recommended first-line antipsychotic for all new schizophrenia presentations given its broadly superior efficacy over other agents.\", \"Clozapine's most dangerous side effect is tardive dyskinesia, making EPS rather than haematological monitoring the key surveillance protocol here.\", \"Clozapine causes agranulocytosis, but monitoring frequency is left entirely to individual prescriber discretion since no formal protocol exists.\"], \"exp\": \"Clozapine is specifically reserved for treatment-resistant schizophrenia — defined as inadequate response to at least two adequate antipsychotic trials — due to its adverse effect profile. Agranulocytosis (potentially fatal neutropenia) is the signature risk, occurring in ~1% and necessitating a mandatory, structured blood monitoring protocol: weekly FBC for the first 18 weeks, then fortnightly, with immediate cessation and haematological referral if counts fall critically. This regulatory monitoring requirement is what defines clozapine's prescribing framework.<br><br>Clozapine's metabolic, cardiovascular, and haematological risks make it inappropriate as a first-line agent regardless of its efficacy. It paradoxically has a very low EPS and tardive dyskinesia risk (unlike typicals), so EPS monitoring is not its defining surveillance requirement — agranulocytosis is. And the blood monitoring protocol is strictly formalised, not discretionary — it is a regulatory condition of clozapine prescribing.\", \"imgId\": null}, {\"id\": 5, \"tag\": \"Antipsychotic Metabolic Side Effects: Olanzapine vs. Aripiprazole\", \"stem\": \"A patient on olanzapine has gained 8kg over four months with a rising fasting glucose. A switch is being considered. Which antipsychotic is better suited to a metabolically vulnerable patient, and what is the mechanism behind olanzapine's metabolic effects?\", \"correct\": \"Aripiprazole has a substantially lower metabolic burden; olanzapine's weight gain and glucose dysregulation relate to its H1 and muscarinic antagonism.\", \"opts\": [\"Aripiprazole has a substantially lower metabolic burden; olanzapine's weight gain and glucose dysregulation relate to its H1 and muscarinic antagonism.\", \"Quetiapine is the preferred switch since it carries no metabolic side effects at all, making it the safest atypical for any metabolically vulnerable patient.\", \"Olanzapine's metabolic effects are driven purely by its D2 blockade, which is why any other D2-blocking antipsychotic carries the same metabolic risk.\", \"Clozapine is the appropriate switch in metabolically vulnerable patients given its uniquely favourable lipid and glucose profile among atypicals.\"], \"exp\": \"Among atypicals, olanzapine and clozapine carry the highest metabolic burden (weight gain, dyslipidaemia, glucose dysregulation), while aripiprazole and ziprasidone carry the lowest. Olanzapine's metabolic effects are driven substantially by histamine H1 antagonism (appetite stimulation, weight gain) and muscarinic antagonism, rather than D2 blockade alone. Aripiprazole, a partial D2 agonist, is a well-supported choice for metabolically vulnerable patients.<br><br>Quetiapine carries meaningful metabolic risk too, particularly at higher doses, so calling it metabolic-burden-free overstates its safety profile considerably. Olanzapine's metabolic effects are not D2-mediated — attributing them to D2 blockade would imply all antipsychotics are equally metabolically risky, which is clearly not true. And clozapine has one of the highest metabolic burdens among all antipsychotics, making it the opposite of an appropriate choice for metabolic safety.\", \"imgId\": null}];\n\n var answers = {};\n var answered = 0;\n var shuffled = {};\n var done = false;\n\n function byId(id) { return document.getElementById(id); }\n function gid(suffix) { return byId(NS + '-' + suffix); }\n\n function shuffleArr(arr) {\n var a = arr.slice(), i, j, tmp;\n for (i = a.length - 1; i > 0; i--) {\n j = Math.floor(Math.random() * (i + 1));\n tmp = a[i]; a[i] = a[j]; a[j] = tmp;\n }\n return a;\n }\n\n function countVal(val) {\n var k, n = 0;\n for (k in answers) {\n if (answers.hasOwnProperty(k) && answers[k] === val) n++;\n }\n return n;\n }\n\n function buildPips() {\n var cont = gid('pips'), i, q, wLine, wPip, line, pip;\n cont.innerHTML = '';\n for (i = 0; i < QS.length; i++) {\n q = QS[i];\n if (i > 0) {\n wLine = document.createElement('div');\n wLine.className = 'mr-pip-wrap';\n line = document.createElement('div');\n line.className = 'mr-pip-line';\n line.id = NS + '-pl' + q.id;\n wLine.appendChild(line);\n cont.appendChild(wLine);\n }\n wPip = document.createElement('div');\n wPip.className = 'mr-pip-wrap';\n pip = document.createElement('div');\n pip.className = 'mr-pip';\n pip.id = NS + '-pip' + q.id;\n pip.textContent = String(q.id);\n wPip.appendChild(pip);\n cont.appendChild(wPip);\n }\n }\n\n function build() {\n var cont, i, q, opts, card, top, numDiv, meta, tag, stem,\n rule, optsDiv, expDiv, lbl, txt, imgDiv, imgSrc, j,\n optEl, ltrSpan, txtSpan;\n\n cont = gid('cases');\n cont.innerHTML = '';\n answers = {}; answered = 0; shuffled = {}; done = false;\n gid('score').style.display = 'none';\n buildPips();\n\n for (i = 0; i < QS.length; i++) {\n q = QS[i];\n opts = shuffleArr(q.opts);\n shuffled[q.id] = opts;\n\n card = document.createElement('div');\n card.className = 'mr-case';\n\n top = document.createElement('div');\n top.className = 'mr-case-top';\n\n numDiv = document.createElement('div');\n numDiv.className = 'mr-num';\n numDiv.textContent = q.id < 10 ? '0' + q.id : String(q.id);\n\n meta = document.createElement('div');\n meta.className = 'mr-meta';\n\n tag = document.createElement('div');\n tag.className = 'mr-tag';\n tag.innerHTML = q.tag;\n\n stem = document.createElement('div');\n stem.className = 'mr-stem';\n stem.innerHTML = q.stem;\n\n meta.appendChild(tag);\n meta.appendChild(stem);\n top.appendChild(numDiv);\n top.appendChild(meta);\n card.appendChild(top);\n\n rule = document.createElement('div');\n rule.className = 'mr-rule';\n card.appendChild(rule);\n\n optsDiv = document.createElement('div');\n optsDiv.className = 'mr-opts';\n\n for (j = 0; j < opts.length; j++) {\n optEl = document.createElement('div');\n optEl.className = 'mr-opt';\n optEl.id = NS + '-o' + q.id + '-' + j;\n optEl.setAttribute('role', 'button');\n optEl.setAttribute('tabindex', '0');\n\n ltrSpan = document.createElement('span');\n ltrSpan.className = 'mr-ltr';\n ltrSpan.textContent = LTRS[j];\n\n txtSpan = document.createElement('span');\n txtSpan.className = 'mr-opt-text';\n txtSpan.innerHTML = opts[j];\n\n optEl.appendChild(ltrSpan);\n optEl.appendChild(txtSpan);\n optsDiv.appendChild(optEl);\n\n (function (qid, oi) {\n optEl.addEventListener('click', function () { pick(qid, oi); });\n }(q.id, j));\n }\n card.appendChild(optsDiv);\n\n expDiv = document.createElement('div');\n expDiv.className = 'mr-exp';\n expDiv.id = NS + '-exp' + q.id;\n\n lbl = document.createElement('div');\n lbl.className = 'mr-exp-lbl';\n lbl.textContent = 'Debrief';\n\n txt = document.createElement('div');\n txt.className = 'mr-exp-text';\n txt.innerHTML = q.exp;\n\n expDiv.appendChild(lbl);\n expDiv.appendChild(txt);\n\n if (q.imgId) {\n imgSrc = byId(q.imgId);\n if (imgSrc) {\n imgDiv = document.createElement('div');\n imgDiv.innerHTML = imgSrc.innerHTML;\n expDiv.appendChild(imgDiv);\n }\n }\n\n card.appendChild(expDiv);\n cont.appendChild(card);\n }\n }\n\n function pick(qid, oi) {\n var q, opts, i, el, correct;\n if (answers[qid] !== undefined || done) return;\n\n q = null;\n for (i = 0; i < QS.length; i++) {\n if (QS[i].id === qid) { q = QS[i]; break; }\n }\n if (!q) return;\n\n opts = shuffled[qid];\n correct = (opts[oi] === q.correct);\n answers[qid] = correct ? 'c' : 'w';\n answered++;\n\n for (i = 0; i < opts.length; i++) {\n el = byId(NS + '-o' + qid + '-' + i);\n if (opts[i] === q.correct) {\n el.className = 'mr-opt correct locked';\n } else if (i === oi) {\n el.className = 'mr-opt wrong locked';\n } else {\n el.className = 'mr-opt dimmed locked';\n }\n }\n\n byId(NS + '-exp' + qid).style.display = 'block';\n byId(NS + '-pip' + qid).className = 'mr-pip ' + (correct ? 'correct' : 'wrong');\n\n if (qid > 1) {\n var pl = gid('pl' + qid);\n if (pl) pl.className = 'mr-pip-line done';\n }\n }\n\n function showScore() {\n var c, w, s, net, pct, disp, verdicts, vi, sc;\n if (done) return;\n done = true;\n\n c = countVal('c');\n w = countVal('w');\n s = TOTAL - answered;\n net = (c * 4) - w;\n pct = Math.max(0, Math.round((net \/ MAX) * 100));\n disp = Math.min(100, Math.max(0, pct));\n\n gid('ring').style.background =\n 'conic-gradient(#34547A ' + disp + '%, #D8E0E8 0%)';\n\n gid('pct').textContent = pct + '%';\n gid('net').textContent = 'Net Score: ' + net + ' \/ ' + MAX;\n\n verdicts = [[5, \"Consultant-grade. You moved through antipsychotic pharmacology without a single hesitation — the kind of round that should feel almost too easy, because it means the pattern recognition is finally automatic.\"], [4, \"Strong round. One case caught you out, but your reasoning on the rest was sound — go back and read the debrief on the miss closely, it's usually a single discriminator hiding in the stem.\"], [3, \"Solid middle ground. You know the core framework but a couple of the finer distinctions slipped — re-run this round in a day or two once it's had time to settle.\"], [2, \"The foundations are there, but today wasn't your day on antipsychotic pharmacology. Don't chase the score — chase the two or three concepts the wrong answers kept circling back to.\"], [0, \"Rough round — and that's fine. This is exactly the material PG exams quietly love to test from odd angles. Read every debrief slowly, then come back and run it again.\"]];\n gid('verdict').textContent = verdicts[verdicts.length - 1][1];\n for (vi = 0; vi < verdicts.length; vi++) {\n if (c >= verdicts[vi][0]) {\n gid('verdict').innerHTML = verdicts[vi][1];\n break;\n }\n }\n\n gid('ct-c').textContent = '\\u2705 ' + c + ' Correct';\n gid('ct-w').textContent = '\\u274C ' + w + ' Wrong';\n gid('ct-s').textContent = '\\u23ED ' + s + ' Skipped';\n\n sc = gid('score');\n sc.style.display = 'block';\n sc.scrollIntoView({ behavior: 'smooth', block: 'center' });\n }\n\n function tryInit() {\n var sentinel = document.getElementById(NS + '-sentinel');\n var submit = document.getElementById(NS + '-submit');\n var retry = document.getElementById(NS + '-retry');\n if (!sentinel || !submit || !retry) {\n setTimeout(tryInit, 80);\n return;\n }\n submit.addEventListener('click', showScore);\n retry.addEventListener('click', function () {\n build();\n window.scrollTo(0, 0);\n });\n var bar = document.getElementById(NS + '-progress');\n if (bar && window.IntersectionObserver) {\n new IntersectionObserver(function (entries) {\n bar.className = entries[0].isIntersecting ? 'mr-progress' : 'mr-progress visible';\n }, { threshold: 0 }).observe(sentinel);\n }\n build();\n }\n\n tryInit();\n\n}());\n<\/script>\n\n\n","protected":false},"excerpt":{"rendered":"<p>Morning Rounds · Psychiatry · Psychopharmacology II Morning Rounds · Psychiatry Series · Round 05 Psychopharmacology II —Antipsychotics, Movement Disorders & Clozapine Five cases · EPS mechanism, NMS vs. serotonin syndrome, tardive dyskinesia & metabolic burden · Trust your instinct 5 Cases +4 \/ −1 scoring Options reshuffled Submit for Debrief Round Complete 0% net… <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[74,94],"tags":[82,83],"class_list":["post-37208","post","type-post","status-publish","format-standard","hentry","category-morning-rounds","category-psychiatry","tag-cms","tag-neet-pg"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Psychopharmacology II \u2014 Antipsychotics, Movement Disorders & Clozapine - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Psychopharmacology II \u2014 Antipsychotics, Movement Disorders & Clozapine - atsixty\" \/>\n<meta property=\"og:description\" content=\"Morning Rounds · Psychiatry · Psychopharmacology II Morning Rounds · Psychiatry Series · Round 05 Psychopharmacology II —Antipsychotics, Movement Disorders & Clozapine Five cases · EPS mechanism, NMS vs. serotonin syndrome, tardive dyskinesia & metabolic burden · Trust your instinct 5 Cases +4 \/ −1 scoring Options reshuffled Submit for Debrief Round Complete 0% net… \" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-04T02:20:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-04T02:20:34+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Psychopharmacology II \u2014 Antipsychotics, Movement Disorders & Clozapine\",\"datePublished\":\"2026-07-04T02:20:33+00:00\",\"dateModified\":\"2026-07-04T02:20:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\\\/\"},\"wordCount\":62,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"keywords\":[\"CMS\",\"NEET-PG\"],\"articleSection\":[\"Morning Rounds\",\"Psychiatry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\\\/\",\"name\":\"Psychopharmacology II \u2014 Antipsychotics, Movement Disorders & Clozapine - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-07-04T02:20:33+00:00\",\"dateModified\":\"2026-07-04T02:20:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/morning-rounds\\\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Psychopharmacology II \u2014 Antipsychotics, Movement Disorders & Clozapine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Psychopharmacology II \u2014 Antipsychotics, Movement Disorders & Clozapine - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/","og_locale":"en_US","og_type":"article","og_title":"Psychopharmacology II \u2014 Antipsychotics, Movement Disorders & Clozapine - atsixty","og_description":"Morning Rounds · Psychiatry · Psychopharmacology II Morning Rounds · Psychiatry Series · Round 05 Psychopharmacology II —Antipsychotics, Movement Disorders & Clozapine Five cases · EPS mechanism, NMS vs. serotonin syndrome, tardive dyskinesia & metabolic burden · Trust your instinct 5 Cases +4 \/ −1 scoring Options reshuffled Submit for Debrief Round Complete 0% net… ","og_url":"https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/","og_site_name":"atsixty","article_published_time":"2026-07-04T02:20:33+00:00","article_modified_time":"2026-07-04T02:20:34+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Psychopharmacology II \u2014 Antipsychotics, Movement Disorders & Clozapine","datePublished":"2026-07-04T02:20:33+00:00","dateModified":"2026-07-04T02:20:34+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/"},"wordCount":62,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"keywords":["CMS","NEET-PG"],"articleSection":["Morning Rounds","Psychiatry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/","url":"https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/","name":"Psychopharmacology II \u2014 Antipsychotics, Movement Disorders & Clozapine - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-07-04T02:20:33+00:00","dateModified":"2026-07-04T02:20:34+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/morning-rounds\/psychopharmacology-ii-antipsychotics-movement-disorders-clozapine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Psychopharmacology II \u2014 Antipsychotics, Movement Disorders & Clozapine"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=37208"}],"version-history":[{"count":1,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37208\/revisions"}],"predecessor-version":[{"id":37209,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/37208\/revisions\/37209"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=37208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=37208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=37208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}